Key takeaways
- • Trial: STEP-5 (NCT03693430) — Phase 3, 304 participants over 104 weeks.
- • Drug studied: Wegovy (Semaglutide) — FDA-approved branded product.
- • Primary endpoint: Percent change in body weight from baseline to week 104
- • Key result: Mean weight loss 15.2% on semaglutide 2.4mg vs 2.6% on placebo at 2 years
- • Published: Nature Medicine, 2022.
Study design
STEP-5 was a phase 3 randomized controlled trial enrolling 304 participants over 104 weeks. The trial studied Wegovy (Semaglutide) for obesity / overweight and was published in Nature Medicine in 2022.
Primary endpoint
Percent change in body weight from baseline to week 104
Key results
| Measure | Value |
|---|---|
| Headline result | Mean weight loss 15.2% on semaglutide 2.4mg vs 2.6% on placebo at 2 years |
| Mean weight loss (highest dose arm) | 15.2% |
| Participants | 304 |
| Duration | 104 weeks |
| Phase | Phase 3 |
Citation
STEP-5. Published in Nature Medicine, 2022.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Wegovy drug page — pricing, FDA status, side effects, alternatives
- All semaglutide trials
- GLP-1 clinical trials database
Other Wegovy trials
- STEP-1 — Mean weight loss 14
- STEP-2 — Mean weight loss 9
- STEP-3 — Mean weight loss 16
- STEP-4 — Participants continuing semaglutide lost an additional 7
- STEP-TEENS — Mean BMI change -16
Other Semaglutide trials
- SUSTAIN-1 (Ozempic) — HbA1c reduction 1
- SUSTAIN-6 (Ozempic) — 26% relative risk reduction in MACE on semaglutide vs placebo (HR 0
Important: This trial was conducted on the FDA-approved branded product Wegovy. Compounded versions of Semaglutide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.